Gerresheimer reports strong revenues and earnings growth in the second quarter

Duesseldorf (ots) -

- Cross-reference: Press release including Group Key Figures is
available at
http://www.presseportal.de/pm/9072/gerresheimer_ag -

- Group revenues grow by 7.6 percent at constant exchange rates in
the second quarter of 2011
- Adjusted EBITDA margin is 19.8 percent
- Net income increases to EUR 13.3m
- Successful conclusion of refinancing

Gerresheimer AG, one of the leading global suppliers to the pharma
and healthcare industry, has closed successfully the second quarter
of the 2011 financial year. "We have achieved strong growth in
revenues and net income. Our Moulded Glass and Plastic Systems
Divisions have performed particularly well. We have also strengthened
our operations in South America, a strategically important market for
us, through our acquisition of Vedat," said Uwe Röhrhoff, CEO of
Gerresheimer AG.

Gerresheimer was able to achieve marked growth in revenues in the
second quarter of the 2011 financial year (March 1, 2011 to May 31,
2011) of 5.9 percent to EUR 284.5m. At constant exchange rates,
revenue growth was 7.6 percent. The Moulded Glass and Plastics
Systems Divisions played an important role in generating this strong
growth. Growth drivers of the Plastic Systems division included
inhalers, insulin pens, diagnostic systems and plastic packaging
products. Vedat, the company that Gerresheimer acquired in March, has
an excellent position in the South American primary pharmaceutical
plastic packaging market and has contributed to the positive
development. Gerresheimer recently announced plans to extend its
Czech Republic plant, being part of the fast-growing Plastic Systems
division.

Gerresheimer reports adjusted EBITDA of EUR 56.3m (prior year: EUR
56.3m) for the second quarter of 2011. The adjusted EBITDA margin was
19.8 percent (Q2 2010: 20.9 percent). Scheduled overhauls of furnaces
and capacity restrictions on prefillable syringe system production
were due in the second quarter. Net income increased year on year,
despite one-off expenses in connection with refinancing, by EUR 2.1m
to EUR 13.3m. Adjusted earnings per share increased over the previous
year's quarter from EUR 0.59 to EUR 0.69.

Net financial debt has declined by EUR 4.1m to EUR 404.6m since
the prior year, despite the costs incurred in connection with the
Vedat acquisition, dividend payment and refinancing. In May,
Gerresheimer concluded the refinancing process, which it had started
ahead of schedule, with five and seven-year maturities.

"As a full-service partner for glass and plastics products and
systems for the global pharma and healthcare industry we have a
unique positioning. There is worldwide growth in demand for
intelligent drug delivery and primary packaging solutions. Our
competence enables us to make a decisive contribution to health and
well-being," said Röhrhoff.

Outlook

Gerresheimer is expecting growth in revenues at constant exchange
rates of six to seven percent, including the Vedat business, and an
adjusted EBITDA margin of approximately 20 percent in the current
2011 financial year. The investment volume is expected to be around
EUR 80m.

Contact:
Jens Kürten
Director Corporate Communication & Marketing
Telephone +49 211 6181-250
Fax +49 211 6181-241
E-Mail j.kuerten@gerresheimer.com Internet
www.gerresheimer.com